Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.